Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC Meeting Abstract
| Authors: | Hayashi, H.; Yu, H. A.; Baik, C.; Gold, K.; Johnson, M. L.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W. C.; Yang, J. C. H.; Karam, S.; Qui, Z.; Qiu, Y.; Chen, S.; Yu, C.; Janne, P. A. |
| Abstract Title: | Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC |
| Meeting Title: | 2021 Annual Meeting of the Japanese Society of Medical Oncology (JSMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2021 Feb 18-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-07-01 |
| Start Page: | S318 |
| Language: | English |
| ACCESSION: | WOS:000683609100216 |
| DOI: | 10.1016/j.annonc.2021.05.640 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: MO30-5 -- Source: Wos |
